Difference between revisions of "Template:Antithrombotics"
Jump to navigation
Jump to search
blackwiki>NSH002 (tidy up) |
|||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| − | | name | + | | name = Antithrombotics |
| − | | title = [[Antithrombotic]]s ([[ | + | | title = [[Antithrombotic]]s ([[Thrombolytic drug|thrombolytics]], [[anticoagulant]]s and [[antiplatelet drug]]s) ([[ATC code B01|B01]]) |
| − | | state = {{{state|autocollapse}}} | + | | state = {{{state<includeonly>|autocollapse</includeonly>}}} |
| − | | bodyclass = hlist | + | | bodyclass = hlist |
| − | | group1 = [[Antiplatelet drug]]s | + | | group1 = [[Antiplatelet drug]]s |
| − | | | + | | list1 = {{Navbox|child |
| − | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] | + | | group1 = [[Glycoprotein IIb/IIIa inhibitors]] |
| − | | | + | | list1 = |
* [[Abciximab]] | * [[Abciximab]] | ||
* [[Eptifibatide]] | * [[Eptifibatide]] | ||
* [[Tirofiban]] | * [[Tirofiban]] | ||
| − | *[[Roxifiban]] | + | * [[Roxifiban]] |
| − | *[[Orbofiban]] | + | * [[Orbofiban]] |
| − | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] | + | | group2 = [[P2Y12|ADP receptor/P2Y<sub>12</sub>]] [[Adenosine diphosphate receptor inhibitor|inhibitors]] |
| − | | | + | | list2 = |
* [[Thienopyridine]]s | * [[Thienopyridine]]s | ||
** [[Clopidogrel]] | ** [[Clopidogrel]] | ||
| Line 27: | Line 27: | ||
** [[Ticagrelor]] | ** [[Ticagrelor]] | ||
| − | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) | + | | group3 = [[Prostaglandin analogue]] ([[Prostacyclin|PGI2]]) |
| − | | | + | | list3 = |
* [[Beraprost]] | * [[Beraprost]] | ||
* [[Iloprost]] | * [[Iloprost]] | ||
| Line 34: | Line 34: | ||
* [[Treprostinil]] | * [[Treprostinil]] | ||
| − | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] | + | | group4 = [[Mechanism of action of aspirin|COX inhibitors]] |
| − | | | + | | list4 = |
* [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | * [[Aspirin|Acetylsalicylic acid/Aspirin]]<sup>#</sup> | ||
* [[Aloxiprin]] | * [[Aloxiprin]] | ||
| Line 42: | Line 42: | ||
* [[Triflusal]] | * [[Triflusal]] | ||
| − | | group5 = [[Thromboxane inhibitors]] | + | | group5 = [[Thromboxane inhibitors]] |
| − | | | + | | list5 = |
* [[Thromboxane synthase inhibitors]] | * [[Thromboxane synthase inhibitors]] | ||
** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+Aspirin]]) | ** [[Dipyridamole]] ([[Acetylsalicylic acid/dipyridamole|+Aspirin]]) | ||
| Line 50: | Line 50: | ||
** [[Terutroban]]<sup>†</sup> | ** [[Terutroban]]<sup>†</sup> | ||
| − | | group6 = [[Phosphodiesterase inhibitor]]s | + | | group6 = [[Phosphodiesterase inhibitor]]s |
| − | | | + | | list6 = |
* [[Cilostazol]] | * [[Cilostazol]] | ||
* [[Dipyridamole]] | * [[Dipyridamole]] | ||
* [[Triflusal]] | * [[Triflusal]] | ||
| − | | group7 = Other | + | | group7 = Other |
| − | | | + | | list7 = |
* [[Cloricromen]] | * [[Cloricromen]] | ||
* [[Ditazole]] | * [[Ditazole]] | ||
* [[Vorapaxar]] | * [[Vorapaxar]] | ||
| − | |||
| − | + | }} | |
| − | |||
| − | + | | group2 = [[Anticoagulant]]s | |
| − | + | | list2 = {{Navbox|child | |
| + | | evenodd = swap | ||
| + | |||
| + | | group1 = [[Vitamin K antagonist]]s<br />(inhibit [[Thrombin|II]], [[Factor VII|VII]], [[Factor IX|IX]], [[Factor X|X]]) | ||
| + | | list1 = | ||
* [[Coumarin]]s: [[Acenocoumarol]] | * [[Coumarin]]s: [[Acenocoumarol]] | ||
* [[Coumatetralyl]] | * [[Coumatetralyl]] | ||
| Line 79: | Line 81: | ||
* Other: [[Tioclomarol]] | * Other: [[Tioclomarol]] | ||
| − | | | + | | group2 = [[Factor Xa]] inhibitors<br />(with some II inhibition) |
| − | | | + | | list2 = {{Navbox|child |
| − | |||
| − | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) | + | | group1 = [[Heparin]] group/<br />[[glycosaminoglycan]]s/<br />(bind [[antithrombin]]) |
| − | | list1 | + | | list1 = |
* [[Low molecular weight heparin]] | * [[Low molecular weight heparin]] | ||
** [[Bemiparin sodium|Bemiparin]] | ** [[Bemiparin sodium|Bemiparin]] | ||
| Line 102: | Line 103: | ||
** [[Sulodexide]] | ** [[Sulodexide]] | ||
| − | | group2 = [[Direct Xa inhibitor]]s | + | | group2 = [[Direct Xa inhibitor]]s |
| − | | | + | | list2 = |
* Xabans | * Xabans | ||
** [[Apixaban]] | ** [[Apixaban]] | ||
| Line 111: | Line 112: | ||
** [[Otamixaban]]<sup>§</sup> | ** [[Otamixaban]]<sup>§</sup> | ||
** [[Rivaroxaban]] | ** [[Rivaroxaban]] | ||
| − | |||
| − | | | + | }} |
| − | | | + | |
| − | * [[ | + | <!-- group3 omitted to preserve alternating striping --> |
| + | |||
| + | | group4 = [[Direct thrombin inhibitor|Direct thrombin (IIa) inhibitor]]s | ||
| + | | list4 = | ||
| + | * [[Direct thrombin inhibitor#Bivalent|Bivalent]]: [[Hirudin]] | ||
** [[Bivalirudin]] | ** [[Bivalirudin]] | ||
** [[Desirudin]] | ** [[Desirudin]] | ||
** [[Lepirudin]] | ** [[Lepirudin]] | ||
| − | * [[ | + | * [[Direct thrombin inhibitor#Univalent|Univalent]]: [[Argatroban]] |
* [[Dabigatran]] | * [[Dabigatran]] | ||
* [[Melagatran]]<sup>‡</sup> | * [[Melagatran]]<sup>‡</sup> | ||
* [[Ximelagatran]]<sup>‡</sup> | * [[Ximelagatran]]<sup>‡</sup> | ||
| − | | | + | | group5 = Other |
| − | | | + | | list5 = |
* [[Antithrombin|Antithrombin III]] | * [[Antithrombin|Antithrombin III]] | ||
* [[Defibrotide]] | * [[Defibrotide]] | ||
| Line 132: | Line 136: | ||
* [[Ramatroban]] | * [[Ramatroban]] | ||
* [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | * [[REG1<!--instantly reversible aptamer-based direct FIXa inhibitor in IIb trials -->]] | ||
| − | |||
| − | | group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s | + | }} |
| − | | | + | |
| − | * [[Plasminogen activator]]s: [[ | + | | group3 = [[Thrombolytic drug]]s/<br />[[fibrinolytic]]s |
| + | | list3 = | ||
| + | * [[Plasminogen activator]]s: [[Recombinant tissue plasminogen activators|r-tPA]] | ||
** [[Tissue plasminogen activator|Alteplase]] | ** [[Tissue plasminogen activator|Alteplase]] | ||
** [[Reteplase]] | ** [[Reteplase]] | ||
| Line 146: | Line 151: | ||
* [[Monteplase]] | * [[Monteplase]] | ||
* [[Streptokinase]]<sup>#</sup> | * [[Streptokinase]]<sup>#</sup> | ||
| − | *Other [[serine endopeptidase]]s: [[Ancrod]] | + | * Other [[serine endopeptidase]]s: [[Ancrod]] |
* [[Brinase]] | * [[Brinase]] | ||
* [[Fibrinolysin]] | * [[Fibrinolysin]] | ||
| − | | group4 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] | + | | group4 = [[Anticoagulant#Anticoagulants outside the body|Non-medicinal]] |
| − | | | + | | list4 = |
* [[Citrate]] | * [[Citrate]] | ||
* [[Ethylenediaminetetraacetic acid|EDTA]] | * [[Ethylenediaminetetraacetic acid|EDTA]] | ||
* [[Oxalate]] | * [[Oxalate]] | ||
| − | | belowstyle = background: transparent; padding: 0px; | + | | belowstyle = background: transparent; padding: 0px; |
| − | | below = {{PharmNavFootnote}} {{Myeloid navs}} | + | | below = {{PharmNavFootnote}} {{Myeloid navs}} |
}}<noinclude> | }}<noinclude> | ||
{{collapsible option}} | {{collapsible option}} | ||
| − | [[Category: | + | [[Category:Drug templates by ATC]] |
| − | |||
| − | |||
</noinclude> | </noinclude> | ||
Revision as of 10:23, 3 June 2015
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Antithrombotics|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Antithrombotics|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Antithrombotics|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.